Sanofi Plunges 9.16% on Disappointing Drug Trial Data

On September 4, 2025, Sanofi's stock experienced a significant drop of 9.16% in pre-market trading, reflecting a notable decline in investor confidence.

Sanofi's stock price took a hit following the release of disappointing late-stage trial data for its experimental inflammatory disease drug, amlitelimab. The data indicated that the drug did not meet the primary endpoint, leading to a sharp decline in investor sentiment. This setback is particularly concerning as Sanofi had high hopes for amlitelimab, which was seen as a potential breakthrough in the treatment of inflammatory diseases.

The negative trial results have raised questions about the future of Sanofi's pipeline and its ability to deliver on its promises. Investors are now closely watching the company's next moves, particularly in terms of how it plans to address this setback and whether it has other promising candidates in the pipeline. The company's management will need to provide clear guidance and reassurance to regain investor trust and stabilize its stock price.